Expanding COVID-19 testing capacity and strengthening testing operations
First written in FY2020. 6 of 8 entries say "Advanced", first in FY2021-Q1. Latest entry: FY2022.
2 other companies' latest entry also says "Restated".
- FY2022RestatedAnnual report
「For COVID-19 (SARS-CoV-2) PCR testing, BML General Laboratory alone is maintaining capacity for approximately 30,000 tests per day in preparation for a further spread of infection. It is also strengthening its full-genome viral sequencing analysis line using next-generation sequencing (NGS) to monitor the emergence and spread of new variants.」
The Group continues to maintain BML General Laboratory's capacity for approximately 30,000 PCR tests per day and to strengthen its full-genome analysis line for monitoring variants. - FY2022-Q3AdvancedAnnual report
「We also conduct five-specimen pooled PCR testing to meet large volumes of requests for infection screening of asymptomatic individuals. Our pooled testing eliminates manual work and uses a specially configured, high-performance liquid handler, enabling us to process more than 10,000 specimens per day.」
The Group performed 5-sample pooled PCR testing to accommodate large-scale screening of asymptomatic individuals and established capacity to process more than 10,000 specimens per day under contract. - FY2022-Q2AdvancedAnnual report
「To enable it to accept large volumes of infection-screening requests from asymptomatic individuals, the Group began 5-sample pooled PCR testing in October. By eliminating manual work and using a specially configured, high-performance liquid handler, the Group has established capacity to process more than 5,000 specimens per day under contract.」
To accommodate large-scale screening of asymptomatic individuals, the Group began 5-sample pooled PCR testing in October. It established operations capable of processing more than 5,000 specimens per day under contract using specially configured liquid-handling equipment. - FY2022-Q1AdvancedAnnual report
「For novel coronavirus (SARS-CoV-2) PCR testing, we had already introduced 2 automated PCR testing platforms capable of processing multiple specimens in December 2020. We subsequently added 1 unit in March 2021 and began operating it in April, then added a further 2 units in June, progressively expanding our testing outsourcing operations. As a result, BML総合研究所 alone acquired testing capacity of more than 30,000 tests per day.」
The Group repeatedly expanded its automated PCR testing platforms and established capacity for more than 30,000 tests per day at BML General Laboratory alone. - FY2021-Q3AdvancedAnnual report
「For COVID-19 (SARS-CoV-2) testing, the Group has been expanding testing capacity and strengthening its operations so that its 10 laboratories nationwide can perform 20,900 tests per day under contract, as announced on 15 December 2020, in response to rapidly growing demand. The number of tests actually performed under contract has also increased substantially as a result.」
For SARS-CoV-2 testing, capacity and operations were expanded so that 10 laboratories nationwide could perform 20,900 tests per day under contract, and the actual number of tests performed under contract also increased substantially. - FY2021-Q2AdvancedAnnual report
「For COVID-19 (SARS-CoV-2) PCR testing, the Group has progressively expanded its testing operations to meet requests from government authorities. BML General Laboratory currently has capacity to perform more than 6,000 tests per day. The Group plans to more than double its testing capacity by early 2021 by expanding testing facilities and introducing large-scale testing equipment, thereby reducing turnaround times.」
The Group progressively expanded its capacity to perform SARS-CoV-2 PCR testing under contract and established capacity for more than 6,000 tests per day at BML General Laboratory. It also disclosed plans to more than double capacity by early 2021 through the expansion of testing facilities and introduction of large-scale testing equipment. - FY2021-Q1AdvancedAnnual report
「For novel coronavirus (SARS-CoV-2) PCR testing, we promptly expanded our testing outsourcing operations in response to requests from the authorities and were able to substantially increase the number of specimens processed per day. Because this PCR testing required us to independently establish a testing line using research-use reagents, our accumulated expertise was fully utilized to increase processing capacity efficiently and with a high degree of accuracy. We are now able to process nearly 4,000 specimens per day and plan to further increase capacity.」
In response to requests from government authorities, the Group expanded its capacity to perform SARS-CoV-2 PCR testing under contract and became capable of processing nearly 4,000 specimens per day. It also disclosed plans for further capacity expansion. - FY2020First statedAnnual report
「While continuing efforts to prevent the spread of COVID-19, the Group will expand capacity and strengthen its testing operations so that it can provide a large volume of COVID-19 tests and fulfil its role as a company supporting Japan's healthcare system.」
The Group identified the expansion of testing capacity and strengthening of testing operations as new measures to enable it to provide a large volume of COVID-19 tests while advancing infection-control efforts.